In-vivo experimental demonstration that hyperhistaminism counteracts tumor-growth
F Dellarovere1, G Broccio, A Granata
1UNIV MESSINA,SCH MED,INST GEN PATHOL,I-98122 MESSINA,ITALY. UNIV MESSINA,SCH MED,CHAIR EMERGENCY MED,I-98122 MESSINA,ITALY.
Oncology Reports
|May 25, 2011
Summary
Long-term histamine administration in rats before and after tumor cell inoculation significantly increased survival rates. This suggests histamine
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Histamine plays a role in immune regulation.
- Hyperhistaminism has been observed to affect tumor growth.
- Allergic individuals show a decreased incidence of neoplastic disease.
Purpose of the Study:
- To investigate the effect of histamine administration on Yoshida ascites sarcoma tumor growth in rats.
- To determine the optimal duration and timing of histamine treatment for anti-tumor effects.
- To explore the potential of histamine as an immunomodulatory agent against cancer.
Main Methods:
- Daily intraperitoneal administration of 0.005 μg of histamine to rats.
- Tumor cell inoculation with Yoshida ascites sarcoma.
- Varying treatment durations before and after tumor inoculation.
- Monitoring survival rates and tumor growth.
Main Results:
- Long-term histamine administration (2 weeks pre-inoculation, 20 days post-inoculation) resulted in 80% survival.
- Short-term treatment (3 days pre- or 20 days post-inoculation) showed no significant anti-tumor effect.
- Induced hyperhistaminism counteracted tumor cell growth effectively with prolonged treatment.
Conclusions:
- Prolonged histamine administration can significantly enhance survival rates in a rat tumor model.
- Histamine's immunoregulatory properties may contribute to reduced cancer incidence in allergic individuals.
- Histamine is integrated into a potent immunoregulatory circuit with potential anti-neoplastic applications.
